Obstetrics and Gynecology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA
Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, District of Columbia, USA.
BMJ Case Rep. 2024 Mar 19;17(3):e258903. doi: 10.1136/bcr-2023-258903.
We describe a case of rapid progression of cervical dysplasia to stage IVB cervical cancer in a previously healthy transgender young adult man on testosterone therapy. The cancer diagnosis came 7 months after routine pap smear showed low-grade dysplasia with high-risk human papillomavirus in preparation for gender-affirming hysterectomy/bilateral-salpingo-oophorectomy. After diagnosis, our patient faced unique challenges as a transgender man receiving gynecologic oncology care. This case highlights the challenges of and barriers to cervical cancer screening and treatment that transgender men confront. This case also considers whether gender-affirming testosterone therapy is associated with cervical cancer risk. We offer suggestions on how to improve cervical cancer screening and treatment for the transgender population.
我们描述了一例先前健康的跨性别年轻男性在接受睾丸酮治疗后，宫颈发育不良迅速进展为 IVB 期宫颈癌。该癌症诊断是在常规巴氏涂片显示低级别上皮内瘤变和高危人乳头瘤病毒后 7 个月发现的，当时正在准备进行性别肯定性子宫切除术/双侧输卵管卵巢切除术。诊断后，我们的患者作为一名接受妇科肿瘤学治疗的跨性别男性，面临着独特的挑战。该病例突出了跨性别男性在宫颈癌筛查和治疗方面面临的挑战和障碍。该病例还考虑了性别肯定性睾丸酮治疗是否与宫颈癌风险相关。我们就如何改善跨性别人群的宫颈癌筛查和治疗提出了建议。
